Helicobacter pylori and Related Gastrointestinal Diseases: Infection, Treatment, Prevention, and Beyond

Dear Colleagues,

Helicobacter pylori (H. pylori) is recognized as the primary causative agent of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. This pathogen is implicated in a range of extra-gastrointestinal diseases. The global rise in antimicrobial resistance has led to a significant decrease in the effectiveness of standard triple therapy, now considered inadequate in many regions. Innovative approaches such as bismuth quadruple therapy, non-bismuth quadruple therapy (including sequential, concomitant, and hybrid therapies), high-dose dual therapy, vonoprazan triple therapy, and vonoprazan–tetracycline therapy have been developed to improve H. pylori eradication rates.

Despite these advances, the optimal first-line therapy offering the highest eradication rate with minimal side effects remains elusive. Additionally, the potential of vaccines to prevent the transmission of H. pylori is still not fully understood, continuing to present a significant challenge to gastroenterologists 40 years post discovery.

We invite investigators to submit original research and review articles that explore recent advances in understanding the pathogenesis of H. pylori, evaluate promising first-line and rescue therapies, and discuss strategies for vaccination against H. pylori infection. Potential topics may include, but are not limited to, the following:

• The epidemiology of H. pylori infection and its public health implications.
• Molecular interactions between H. pylori and the human gastric mucosa.
• Extra-gastrointestinal manifestations of H. pylori infection.
• Advances in diagnosing H. pylori infection.
• Emerging first-line and second-line therapies against H. pylori.
• Current and future strategies for preventing gastric cancer beyond H. pylori infection.

The development and implications of vaccinating against H. pylori.

Dr. Ping I. Hsu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.